Lyell Immunopharma Inc 2025年季度报告

SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period endedMarch31, 2025 OR TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period fromtoCommission File Number:001-40502 Lyell Immunopharma, Inc. (Exact Name of Registrant as Specified in its Charter) Name of each exchange on which registered Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements forthe past 90 days.Yes☒No☐ Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule12b-2 of the Exchange Act. If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new orrevised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐ Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes☐No☒ As of May8, 2025, the registrant had295,337,557shares of common stock, $0.0001 par value per share, outstanding. Lyell Immunopharma, Inc. Table of Contents Special Note Regarding Forward-Looking StatementsPART I—FINANCIAL INFORMATIONItem 1.Financial Statements (unaudited)Condensed Consolidated Balance SheetsCondensed Consolidated Statements of Operations and Comprehensive LossCondensed Consolidated Statements of Stockholders’EquityCondensed Consolidated Statements of Cash FlowsNotes to Unaudited Condensed Consolidated Financial StatementsItem 2.Management’s Discussion and Analysis of Financial Condition and Results of OperationsItem 3.Quantitative and Qualitative Disclosures About Market RiskItem 4.Controls and ProceduresPART II—OTHER INFORMATIONItem 1.Legal ProceedingsItem 1A.Risk FactorsItem 2.Unregistered Sales of Equity Securities and Use of ProceedsItem 3.Defaults Upon Senior SecuritiesItem 4.Mine Safety DisclosuresItem 5.Other InformationItem 6.ExhibitsSignature SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements. All statements other than statements of historicalfacts contained in this Quarterly Report on Form 10-Q, including statements regarding our future results of operations and financialposition, business strategy, product candidates, planned nonclinical studies and clinical trials, results of nonclinical studies and clinicaltrials, research and development costs, planned regulatory submissions, regulatory approvals and the timing and likelihood of success,as well as plans and objectives of management for future operations, are forward-looking statements. These statements involve knownand unknown risks, uncertainties and other important factors that are in some cases beyond our control and may cause our actualresults, performance or achievements to be materially different from any future results, performance or achievements expressed orimplied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “would,” “expect,”“plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue,” or the negativeof these terms or other similar expressions. Forward-looking statements contained in this Quarterly Report on Form 10-Q include, butare not limited to, statements about: •the sufficiency of our existing cash to fund our future operating expenses and capital expenditure requirements;•the accuracy and timing of our estimates regarding expenses, revenue opportunities, capital requirements and needs foradditional financing;•the scope, progress, results and costs of developing LYL314 (formerly IMPT-314) or any other product candidates we maydevelop or acquire, including both nonclinical studies and clinical trials;•the timing and costs involved in obtaining and maintaining regulatory approvals of LYL314 or any other product candidateswe may develop or acquire, and the timing or likelihood of regulatory filings and approvals, including any expectations orplans regarding seeking or maintaining special designations, such as Regenerative Medicine Advanced Therapy designation,Orphan Drug designation or Fast Track designation, for our product candidates for various diseases;•our plans relating to the commercialization of LYL314 or any other product candidates we may develop o